Stock data
BridgeBio Pharma, Inc. (BBIO)
BridgeBio Pharma, Inc. (BBIO) reported revenue of US$502.08M and net income of -US$732.94M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$502.08M | — | -US$523.41M | -US$732.94M | — |
| 2024 | US$221.90M | — | -US$592.97M | -US$543.35M | — |
| 2023 | US$9.30M | — | -US$607.37M | -US$653.25M | — |
| 2022 | US$77.65M | — | -US$512.20M | -US$484.65M | — |
| 2021 | US$69.72M | — | -US$576.63M | -US$586.45M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$243.68M | -US$155.89M | — |
| 2026-03-31 | US$194.51M | -US$166.56M | — |
| 2025-12-31 | US$154.18M | -US$194.63M | — |
| 2025-09-30 | US$120.70M | -US$184.94M | — |
| 2025-06-30 | US$110.56M | -US$183.76M | — |
| 2025-03-31 | US$116.63M | -US$169.61M | — |
| 2024-12-31 | US$5.88M | -US$267.39M | — |
| 2024-09-30 | US$2.73M | -US$164.25M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.